Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7398655 | 0.87 | GAA (0.52) | GAANFKB1NFKB2RELAPLG | |
| SCHEMBL4507930 | 0.82 | GAA (0.47) | GAANFKB1NFKB2RELAPLG | |
| SCHEMBL23282460 | 0.81 | GAA (0.55) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL22728463 | 0.81 | GAA (0.55) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL4506151 | 0.77 | RGS12 (0.33) | CCR2 | |
| SCHEMBL22482790 | 0.76 | GAA (0.52) | GAANFKB1NFKB2RELAF2 | |
| SCHEMBL22482787 | 0.76 | GAA (0.52) | GAANFKB1NFKB2RELAF2 | |
| SCHEMBL8837689 | 0.76 | GAA (0.52) | GAANFKB1NFKB2RELAF2 | |
| SCHEMBL8837694 | 0.76 | GAA (0.52) | GAANFKB1NFKB2RELAF2 | |
| SCHEMBL4985702 | 0.76 | GAA (0.52) | GAANFKB1NFKB2RELAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | AAAS, AMPD2, AMPD3 | GAA 1301/4885NFKB1 1086/4885NFKB2 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.